However, the tumor-killing functions of these tumor-reactive CD8+ T cells were not assessed and whether this personalized DC-based vaccine strategy is capable of improving patient cancer-free survival remains to be assessed in future clinical trials. The gene discussed is CD8A; the disease is cancer.